Belly Bandit® Introduces the Luxetm Belly WrapWhen a Belly Wrap Meets a Corset - You're in Luxe!
LOS ANGELES, Sept. 17, 2019 /PRNewswire-PRWeb/ -- The Luxetm Belly Wrap's patented-design blends the best features of the company's wraps and corsets to create an incredible, form-fitting wrap that provides the ultimate in targeted postpartum compression and support. The Luxetm boasts an innovative design and Belly Bandit's® exclusive Stayputtm technology.
Luxetm Belly Wrap ($99.95)
Features 5 levels of targeted compression for the perfect cinch
Stayputtm Technology to keep Wrap in place and prevent creasing
11" tall in the front and 12" in the back
6 body contouring support panels for a strong, secure hold
Dual closures made of bonded microfiber for maximum adjustability
Arched design helps minimize back bulge
SecureStretchtm fabric for core and back support
"The Luxetm was a decade in the making, and as you'll see, worth the wait," said Jodi Caden, Designer and Co-founder, Belly Bandit®. "We listened to our customers and created a wrap that provides maximum support, while thin and lightweight, so it can be worn comfortably and discreetly under clothes."
Belly Bandit's® proprietary SecureStretchtm fabric applies targeted compression, which may help:
Compress and support the belly, waist and hips
Strengthen core muscles weakened during pregnancy
Promote mobility and ease back pain
Provide comfort after C-section
Encourage better posture, especially important during breastfeeding
The Luxetm Belly Wrap is eligible for insurance reimbursement in the U.S. and on sale now at bellybandit.com.
Belly Bandit® is a for women by women company, dedicated to its mission of empowering women to look and feel their absolute best before, during and after pregnancy. The company has evolved from its signature product, the Belly Bandit®, Belly Wrap and expanded to include, maternity wear, intimates, and a complete line of compression shapewear.
The 31st Canadian Cancer Society (CCS) Daffodil Ball, which took place this evening at Windsor Station in Montreal, raised $1,474,785 to fund innovative research projects and essential support programs for people living with cancer. The largest...
The report titled "Clinical Trials Matching Software Market by Functionality (Analytics & Reporting, Compliance Tracking, Data Management), Deployment (Cloud & Web Based, On-Premise), End-Use - Global Forecast 2024-2030" is now available on...
South Korea's biotechnology company Hyundai Bioscience (CEO Oh Sang-gi, www.hyundaibioscience.com) announced on April 15 that it would carry out global clinical tests aimed at treating all serotypes of Dengue virus infection....
RevolKa Ltd. (Norio Hamamatsu, President & CEO), a venture-backed biotech company providing a game-changing protein engineering technology platform and La Jolla Institute for Immunology (LJI) (Erica Saphire, President & CEO) agreed to start a...
Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved ENTYVIO® (vedolizumab) subcutaneous (SC) administration for maintenance therapy in adults with moderately to severely active Crohn's disease (CD)...